Status: Recruiting
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
This Phase 3 study in adult participants with newly diagnosed low-risk APL will evaluate the efficacy, safety, and PK of an oral capsule formulation of ATO, in combination with ATRA.
Participants needed: 150
Trial details
Phase: Phase 3Age: 18-71Biological sex: AllType: InterventionalSponsor: Quetzal TherapeuticsUpdated: Jun 16, 2026Locations: 7
Eligibility criteria
Informed Consent [+4]
Participants who have significant heart rhythm problems including long QT syndro... [+4]